Clinical trials
Completed Leukemia trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 1 |
| 2002 | 5 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2015 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 45 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Oncology Group | 19 |
| Swiss Cancer Institute | 6 |
| Novartis Pharmaceuticals | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| National Cancer Institute (NCI) | 2 |
| University Hospital Schleswig-Holstein | 2 |
| Becton, Dickinson and Company | 1 |
| Bristol-Myers Squibb | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Heidelberg University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia | 45 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 |
| Lymphoma | 8 |
| Leukemia, Myeloid, Acute | 7 |
| Burkitt Lymphoma | 5 |
| Congenital Abnormalities | 5 |
| Dendritic Cell Sarcoma, Interdigitating | 4 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 |
| Myelodysplastic Syndromes | 4 |
| Leukemia, Erythroblastic, Acute | 3 |
Trials
Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.